Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Communications"
DOI: 10.1002/cac2.12385
Abstract: Treatment options for Chinese patients with locally advanced or metastatic squamous‐cell non‐small‐cell lung cancer (sqNSCLC) after failure of first‐line chemotherapy are limited. This study (ORIENT‐3) aimed to evaluate the efficacy and safety of sintilimab versus… read more here.
Keywords: cell; metastatic squamous; line; treatment ... See more keywords
Cost‐effectiveness of first‐line versus second‐line use of domestic anti‐PD‐1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non‐small cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5440
Abstract: Programmed cell death protein‐1/programmed cell death ligand‐1 (PD‐1/L1) inhibitor is a promising therapeutic option that can be used as either a first‐line or second‐line treatment for driver‐negative advanced or metastatic squamous non‐small cell lung cancers… read more here.
Keywords: cell; metastatic squamous; first line; line ... See more keywords
Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-020-01788-6
Abstract: Background The standard of care for first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) in patients who cannot tolerate platinum-based regimens has not been clarified. We aimed… read more here.
Keywords: metastatic squamous; recurrent metastatic; carcinoma head; cell carcinoma ... See more keywords
Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108).
Sign Up to like & getrecommendations! Published in 2019 at "European journal of cancer"
DOI: 10.1016/j.ejca.2019.08.018
Abstract: BACKGROUND The combination of cisplatin, 5-fluorouracil (5-FU) and cetuximab (PFC) is the reference first-line treatment for recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). We analysed whether treatment intensification by the addition… read more here.
Keywords: metastatic squamous; recurrent metastatic; trial; squamous cell ... See more keywords
Economic burden of chemotherapy-treated recurrent and/or metastatic squamous cell carcinoma of the head and neck in France: real-world data from the permanent sample of national health insurance beneficiaries
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2019.1594837
Abstract: Abstract Aims: Overall survival (OS) of patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) is extremely poor. New therapeutic options emerge but need to establish their economic value.… read more here.
Keywords: metastatic squamous; recurrent metastatic; carcinoma head; cell carcinoma ... See more keywords
Hematological Markers Predict Immune-Related Adverse Events in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Pembrolizumab.
Sign Up to like & getrecommendations! Published in 2025 at "Asia-Pacific journal of clinical oncology"
DOI: 10.1111/ajco.70012
Abstract: BACKGROUND In patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), the correlation between hematological markers and treatment outcomes has been established. However, their predictive role in the development… read more here.
Keywords: recurrent metastatic; squamous cell; patients recurrent; metastatic squamous ... See more keywords
Spontaneous hematoma of the thigh associated with antiproteinase-3 antibody in a patient with metastatic squamous cell carcinoma treated with nivolumab
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/1078155218786352
Abstract: We report an unusual case of spontaneous intramuscular hematoma associated with antiproteinase 3 antibody in a patient with metastatic squamous cell carcinoma receiving nivolumab and the medical literature is reviewed. read more here.
Keywords: metastatic squamous; squamous cell; antiproteinase antibody; associated antiproteinase ... See more keywords
Randomised phase II study with cetuximab in combination with 5-FU and cisplatin or carboplatin versus cetuximab in combination with paclitaxel and carboplatin for treatment of patients with relapsed or metastatic squamous cell carcinoma of the head and neck (CETMET trial).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.6032
Abstract: 6032Background: Platinum-based chemotherapy with cetuximab is the standard of care for relapsed or metastatic squamous cell carcinoma of the head and neck (SCCHN). The aim of this trial was to inve... read more here.
Keywords: combination; metastatic squamous; relapsed metastatic; squamous cell ... See more keywords
Cost-effectiveness of first-line pembrolizumab plus chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e20703
Abstract: e20703 Background: Trial results from KEYNOTE-407 have recently led to the FDA approval for pembrolizumab + carboplatin + paclitaxel/nab-paclitaxel (pembrolizumab+chemo) in previously untreated metastatic squamous NSCLC. This is the only first-line indication for squamous NSCLC… read more here.
Keywords: pembrolizumab; metastatic squamous; cost effectiveness; first line ... See more keywords
Real-world effectiveness and healthcare utilization of nivolumab for recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHNC): A real-world population-based study.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e18040
Abstract: e18040 Background: Nivolumab was the first immunotherapy to have shown efficacy in platinum-resistant recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHNC) in the CheckMate-141 trial. Prior to its introduction, patients with… read more here.
Keywords: real world; recurrent metastatic; population; world ... See more keywords
Personalized oncogenomic analysis of metastatic squamous cell carcinoma of the anus: Utilizing whole-genome sequencing to guide clinical decision-making.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.4_suppl.11
Abstract: 11 Background: Metastatic squamous cell carcinoma of the anus (SCCA) is associated with significant morbidity and mortality. Due to its relative rarity, there is limited evidence to support systemic therapy regimens informed by genomic data.… read more here.
Keywords: analysis; whole genome; cell; squamous cell ... See more keywords